Step 1 topics → Musculoskeletal, Skin, and Connective Tissue → Mixed Connective Tissue Disease

Mixed Connective Tissue Disease

USMLE Step 1 trap: Confuses the defining antibody of MCTD (anti-U1 RNP) with ANA or anti-dsDNA. MCTD is defined by high-titer anti-U1 RNP antibodies in the setting of overlapping features of SLE, scleroderma, and polymyositis.

Mixed connective tissue disease (MCTD) is an overlap syndrome combining features of SLE, scleroderma, and polymyositis under one diagnosis — tied together by a single defining antibody: high-titer anti-U1 RNP. On USMLE Step 1, students who haven't locked in that antibody default to ANA or anti-dsDNA and get it wrong; ANA is positive in virtually every connective tissue disease and carries no specificity here, and anti-dsDNA is specific for SLE, not MCTD. The key insight is that MCTD is not just 'a little of everything' — it has specific cardinal features that show up early and consistently, and Step 1 tests whether you can recognize them.

The exam typically approaches MCTD through a short clinical vignette: a patient with Raynaud phenomenon, puffy/swollen hands, inflammatory arthritis, and myositis — and then asks you to identify the diagnostic antibody or name the condition. The trap is that these patients are also ANA-positive (almost universally), so students who don't have the anti-U1 RNP answer locked in will default to ANA or anti-dsDNA and get it wrong. Anti-dsDNA is specific for SLE, not MCTD — that distinction is fair game.

MCTD is low-yield overall on USMLE Step 1, but if it does appear, the question will almost certainly hinge on two things: the defining antibody (anti-U1 RNP) and the hallmark early features (Raynaud + swollen hands + overlap features). Know those cold and you won't be caught off guard.

From real student decks
46%have cards covering this topic
22%have mature cards

Common misconceptions

Common mistake
Wrong: MCTD is defined by a positive ANA or anti-dsDNA antibody.
Right: MCTD is defined by high-titer anti-U1 RNP antibodies in the setting of overlapping features of SLE, scleroderma, and polymyositis.
ANA is positive in MCTD, but it's positive in nearly every connective tissue disease — it has no specificity here. Anti-dsDNA is the high-specificity antibody for SLE, not MCTD. The antibody that defines MCTD and separates it from other overlap syndromes is high-titer anti-U1 RNP. When you see an overlap syndrome on Step 1, anti-U1 RNP is the answer the question is hunting for.
Common mistake
Gap: Misses that Raynaud phenomenon and swollen hands are hallmark early features of MCTD
MCTD classically presents with Raynaud phenomenon, swollen hands, inflammatory arthritis, esophageal dysmotility, and myositis as its cardinal overlap features.
Students often remember that MCTD has 'SLE + scleroderma + polymyositis features' but blank on which specific features appear first and most consistently. Raynaud phenomenon and swollen, puffy hands are the hallmark early findings — they show up before the full overlap picture develops. Pair those with inflammatory arthritis, esophageal dysmotility, and myositis to complete the classic MCTD picture. If a vignette highlights puffy hands and Raynaud in the context of an overlap syndrome, MCTD should jump to mind immediately.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Given a patient with overlapping features of SLE, scleroderma, and polymyositis, identify anti-U1 RNP as the defining antibody of MCTD — not ANA or anti-dsDNA.
  2. Recognize the cardinal clinical presentation of MCTD: Raynaud phenomenon, swollen/puffy hands, inflammatory arthritis, esophageal dysmotility, and myositis as the classic overlap features.

Can you avoid these mistakes?

A 35-year-old woman presents with Raynaud phenomenon, swollen fingers, proximal muscle weakness, and difficulty swallowing. Labs show a high-titer positive ANA. Which specific antibody would confirm the diagnosis of MCTD?
A patient is found to have anti-U1 RNP antibodies. Which three classic connective tissue diseases contribute overlapping features to this condition, and what are the two hallmark early clinical findings?
Why is a positive ANA insufficient to diagnose MCTD, even in a patient with overlap features of multiple connective tissue diseases?
A question stem describes a patient with features of both SLE and scleroderma. The labs show anti-dsDNA positive. Does this point toward MCTD or SLE, and why?

Related topics

Bone Cells and Matrix Endochondral vs Membranous Ossification Fracture Healing Stages Compartment Syndrome

See how your Anki deck covers this topic.

Upload your deck for a free audit →